NCT06582602View on ClinicalTrials.gov

A Study of MK-2060 in Healthy Participants (MK-2060-016)

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

April 18, 2025

Study Completion Date

April 18, 2025

Conditions
Venous Thrombosis
Interventions
BIOLOGICAL

MK-2060

Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

BIOLOGICAL

Placebo

Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.

Trial Locations (2)

33147

Advanced Pharma CR, LLC ( Site 0002), Miami

37920

Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06582602 - A Study of MK-2060 in Healthy Participants (MK-2060-016) | Biotech Hunter | Biotech Hunter